2026 Current Concepts in Head and Neck Surgery: "Radiation Fibrosis Underneath it all: Imaging and Trials"

Delivered in-person Hickey Auditorium, MDACC, Houston, 2026-11-14T1025 adiation-induced normal tissue injury in the head and neck is a continuum, not a set of discrete toxicities: acute inflammation gives way to lymphedema, then fibrosis, then fibroatrophy, driven by canonical TGF-β/Smad and TNF-α/NF-κB signaling. The central premise is a “reversibility window,” a sub-acute edematous phase that may be modifiable before injury becomes refractory and symptomatic.Post-radiation edema is nearly ubiquitous yet rarely addressed. Cumulative incidence approaches 70% for external and roughly 45% for internal lymphedema, with risk scaling by nodal burden, dissection extent, and dose. Current assessment tools are limited. HN-LEF and the revised Patterson scale are clinically usable but subjective, while CT-LEFAT fat-stranding grading showed only modest discrimination among radiation oncologist raters (mean AUC about 0.70).Quantitative MRI is positioned as the better biomarker. Serial studies show dose-dependent T1/T2 signal change in swallowing muscles, association with conversion to moderate/severe dysphagia (DIGEST ≥2), and signal patterns that separate HN-LEF categories, with muscle volume falling as lymphedema-fibrosis severity rises. A prospective Bayesian R-IDEAL stage 2b cohort found greater superior constrictor T1 relaxometry change in patients with DIGEST ≥2 (posterior probabilities up to 95%; AUC 0.73).Germline risk complements imaging. The TGF-β1 C-509T promoter polymorphism predicted roughly fourfold higher grade 2+ fibrosis in a randomized breast trial (13.8% vs 3.8%), and genotype-dependent osteoradionecrosis risk has been reported in head and neck cohorts.Management consensus remains weak, per an international Delphi study, which motivates two Bayesian trials of repurposed agents:STOP4-LATE-FIBROSE (NCT06494111): registry-embedded, 2:2:1 randomization to prophylactic pravastatin, pentoxifylline/tocopherol, or control during months 6–18 post-radiation.REVERSE-FIBROSE (NCT06912763): adaptive platform randomizing equally among pravastatin, pentoxifylline/tocopherol, ketoprofen, pirfenidone, and standard of care, with HN-LEF, Patterson, DIGEST, cervical range of motion, and quantitative MRI endpoints.

Authors

Publication Details

Journal
Figshare
Published
2026-11-14
DOI
https://doi.org/10.6084/m9.figshare.35011513
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

2026 Current Concepts in Head and Neck Surgery: "Radiation Fibrosis Underneath it all: Imaging and Trials"

Clifton David Fuller
Figshare
Head and Neck Cancer Studies
article

2026 Current Concepts in Head and Neck Surgery: "Radiation Fibrosis Underneath it all: Imaging and Trials"

Clifton David Fuller
article en

Abstract

Delivered in-person Hickey Auditorium, MDACC, Houston, 2026-11-14T1025 adiation-induced normal tissue injury in the head and neck is a continuum, not a set of discrete toxicities: acute inflammation gives way to lymphedema, then fibrosis, then fibroatrophy, driven by canonical TGF-β/Smad and TNF-α/NF-κB signaling. The central premise is a “reversibility window,” a sub-acute edematous phase that may be modifiable before injury becomes refractory and symptomatic.Post-radiation edema is nearly ubiquitous yet rarely addressed. Cumulative incidence approaches 70% for external and roughly 45% for internal lymphedema, with risk scaling by nodal burden, dissection extent, and dose. Current assessment tools are limited. HN-LEF and the revised Patterson scale are clinically usable but subjective, while CT-LEFAT fat-stranding grading showed only modest discrimination among radiation oncologist raters (mean AUC about 0.70).Quantitative MRI is positioned as the better biomarker. Serial studies show dose-dependent T1/T2 signal change in swallowing muscles, association with conversion to moderate/severe dysphagia (DIGEST ≥2), and signal patterns that separate HN-LEF categories, with muscle volume falling as lymphedema-fibrosis severity rises. A prospective Bayesian R-IDEAL stage 2b cohort found greater superior constrictor T1 relaxometry change in patients with DIGEST ≥2 (posterior probabilities up to 95%; AUC 0.73).Germline risk complements imaging. The TGF-β1 C-509T promoter polymorphism predicted roughly fourfold higher grade 2+ fibrosis in a randomized breast trial (13.8% vs 3.8%), and genotype-dependent osteoradionecrosis risk has been reported in head and neck cohorts.Management consensus remains weak, per an international Delphi study, which motivates two Bayesian trials of repurposed agents:STOP4-LATE-FIBROSE (NCT06494111): registry-embedded, 2:2:1 randomization to prophylactic pravastatin, pentoxifylline/tocopherol, or control during months 6–18 post-radiation.REVERSE-FIBROSE (NCT06912763): adaptive platform randomizing equally among pravastatin, pentoxifylline/tocopherol, ketoprofen, pirfenidone, and standard of care, with HN-LEF, Patterson, DIGEST, cervical range of motion, and quantitative MRI endpoints.

Figshare
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon